Atypical Parkinsonism Genetic Variants
Overview
Atypical parkinsonian disorders are a group of neurodegenerative diseases that share features with [Parkinson's disease](/diseases/parkinsons-disease) but typically have more rapid progression, earlier falls, and poorer response to dopaminergic medications. The main atypical parkinsonian disorders include Progressive Supranuclear Palsy (PSP), Multiple System Atrophy (MSA), and Corticobasal Degeneration (CBD). While these diseases were historically considered sporadic, significant genetic contributions have been identified that provide insights into disease mechanisms and therapeutic targets. [@genomewide]
Genetic studies have revealed distinct genetic architectures for each atypical parkinsonian disorder: [@mashyam2022][@kumar2020]
- Progressive Supranuclear Palsy (PSP): Strong association with [MAPT](/proteins/tau) (microtubule-associated protein tau) H1 haplotype, accounting for ~40% of genetic risk
- Multiple System Atrophy (MSA): Associated with SNCA (alpha-synuclein) variants, [GBA](/entities/gba) (glucocerebrosidase) mutations, and COQ2 variants
- Corticobasal Degeneration (CBD): MAPT mutations and H1 haplotype are major genetic risk factors
Understanding these genetic variants is critical for: [@noveldctn1]
Accurate diagnosis and differential diagnosis
Understanding disease mechanisms
Developing targeted therapies
Genetic counseling for familiesPSP Genetics
...Atypical Parkinsonism Genetic Variants
Overview
Atypical parkinsonian disorders are a group of neurodegenerative diseases that share features with [Parkinson's disease](/diseases/parkinsons-disease) but typically have more rapid progression, earlier falls, and poorer response to dopaminergic medications. The main atypical parkinsonian disorders include Progressive Supranuclear Palsy (PSP), Multiple System Atrophy (MSA), and Corticobasal Degeneration (CBD). While these diseases were historically considered sporadic, significant genetic contributions have been identified that provide insights into disease mechanisms and therapeutic targets. [@genomewide]
Genetic studies have revealed distinct genetic architectures for each atypical parkinsonian disorder: [@mashyam2022][@kumar2020]
- Progressive Supranuclear Palsy (PSP): Strong association with [MAPT](/proteins/tau) (microtubule-associated protein tau) H1 haplotype, accounting for ~40% of genetic risk
- Multiple System Atrophy (MSA): Associated with SNCA (alpha-synuclein) variants, [GBA](/entities/gba) (glucocerebrosidase) mutations, and COQ2 variants
- Corticobasal Degeneration (CBD): MAPT mutations and H1 haplotype are major genetic risk factors
Understanding these genetic variants is critical for: [@noveldctn1]
Accurate diagnosis and differential diagnosis
Understanding disease mechanisms
Developing targeted therapies
Genetic counseling for familiesPSP Genetics
PSP is strongly associated with tau pathology. The MAPT gene H1 haplotype is the major genetic risk factor, increasing risk by 3-5x. Specific mutations like P301L cause familial PSP. [@kumar2020]
See: [PSP Genetic Variants](/diseases/psp-genetic-variants)
MSA Genetics
MSA is characterized by [alpha-synuclein](/proteins/alpha-synuclein) pathology. Genetic variants in SNCA, GBA, and COQ2 contribute to disease risk.
See: [MSA Genetic Variants](/diseases/msa-genetic-variants)
CBD Genetics
CBD shows both tau and [TDP-43](/mechanisms/tdp-43-proteinopathy) pathology. MAPT H1 haplotype and specific mutations are the primary genetic risk factors.
See: [CBD Genetic Variants](/diseases/cbd-genetic-variants)
Major Genetic Risk Factors
MAPT (Microtubule-Associated Protein Tau)
The MAPT gene encodes the tau protein, which is central to several atypical parkinsonian disorders. The H1 haplotype is a major risk factor for both PSP and CBD, increasing susceptibility by approximately 3-5 fold. Specific pathogenic mutations such as P301L, P301S, and R406W cause familial forms of PSP and CBD. These mutations alter tau's ability to bind microtubules and promote aggregation into neurofibrillary tangles. [@kumar2020]
SNCA (Alpha-Synuclein)
SNCA mutations and multiplications are associated with MSA risk. The SNCA H1 haplotype is also a risk factor for PSP. Alpha-synuclein aggregates into glial cytoplasmic inclusions in MSA, distinguishing it from the Lewy bodies seen in PD.
GBA (Glucocerebrosidase)
GBA mutations, which cause Gaucher disease, are significant risk factors for both PD and MSA. Carriers of GBA mutations have a 5-10 fold increased risk of developing MSA. The mechanism involves lysosomal dysfunction and alpha-synuclein aggregation.
COQ2
Variants in the COQ2 gene, which encodes Coenzyme Q10 biosynthesis protein, have been associated with MSA in Japanese populations. COQ2 variants may impair mitochondrial function and increase susceptibility to MSA.
DCTN1 (Dynactin Subunit 1)
DCTN1 variants are associated with Perry disease, an unusual autosomal dominant parkinsonism. The G71S mutation is the most common cause. Patients present with parkinsonism, psychiatric changes, and weight loss. [@noveldctn1]
PLA2G6 (Phospholipase A2, Group VI)
PLA2G6-associated neurodegeneration (PLAN) can present with adult-onset parkinsonism. Phenotypes include dystonia-parkinsonism, iron accumulation, and corticobasal syndrome. [@pla2g6adult]
ATXN2 (Ataxin 2)
ATXN2 CAG repeat expansions are associated with spinocerebellar ataxia type 2 (SCA2) and are also implicated in ALS risk. Intermediate expansions may modify atypical parkinsonism phenotypes. [@atxn2expanding]
Genetic Testing and Clinical Implications
Genetic testing for atypical parkinsonism variants is increasingly important for:
- Differential diagnosis: Genetic signatures can help distinguish between PSP, MSA, CBD, and PD
- Prognosis: Certain mutations are associated with more rapid progression
- Family counseling: Identifies at-risk family members
- Therapeutic trials: Genetic stratification for clinical trials
Therapeutic Implications
Understanding the genetic basis of atypical parkinsonism has led to several therapeutic approaches:
- Tau-targeted therapies: Antisense oligonucleotides and small molecules targeting tau for PSP and CBD
- Alpha-synuclein aggregation inhibitors: Being developed for MSA
- Neuroprotective strategies: Based on understanding of genetic risk pathways
- Gene therapy: Potential for delivering therapeutic genes
- GBA enzyme enhancement: Pharmacological chaperones for GBA-associated cases
See Also
- [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
- [Multiple System Atrophy](/diseases/multiple-system-atrophy)
- [Corticobasal Degeneration](/diseases/corticobasal-degeneration)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [MAPT Gene Variants](/diseases/mapt-variants)
External Links
- [NINDS: PSP Information](https://www.ninds.nih.gov/Disorders/All-Disorders/Progressive-Supranuclear-Palsy-Information-Page)
- [NINDS: MSA Information](https://www.ninds.nih.gov/Disorders/All-Disorders/Multiple-System-Atrophy-Information-Page)
- [CurePSP Foundation](https://www.psp.org/)
- [MSA Coalition](https://www.multiplesystematrophy.org/)
- [ClinicalTrials.gov: Atypical Parkinsonism](https://clinicaltrials.gov/ct2/results?cond=Atypical+Parkinsonism)